Introduction: Oxidative stress and endothelial damage are involved in the development and progression of diabetic nephropathy (DN). In this study, we investigated the effects of nitrosonifedipine (NO-NIF) having antioxidative property on DN with the endothelial dysfunction. Patients (or Materials) and Methods: KKAy mice were used as a model of developing type II diabetes mellitus with the endothelial dysfunction. NO-NIF (30 mg/kg/d) was administrated continuously by intraperitoneally injection for 4 weeks. Histologic changes in the kidney, urinary protein, urinary albumin, oxidative stress, and blood glucose levels were evaluated. Moreover, we also examined whether NO-NIF affected the kidney dysfunction in eNOS knockout mice. Results: In NO-NIF--treated KKAy mice, the urinary protein and albumin were significantly decreased compared with nontreated KKAy mice. The pathologic analysis showed expanded glomerular mesangium in KKAy mice, which was suppressed by NO-NIF administration. However, NO-NIF had no effect on blood glucose in KKAy mice. NO-NIF decreased dihydroethidium staining in the kidney and 8-hydroxy-20-deoxyguanosine in the urine in KKAy mice. The expression of intercellular adhesion molecule-1, an endothelial cell damage marker, was decreased in the kidney by NO-NIF while the podocyte injury marker was not changed. The mRNA expression of TNF-α in kidney was also inhibited by NO-NIF. Furthermore, the administration of NO-NIF also suppressed the expansion of glomerular mesangial area and decreased urinary albumin in eNOS knockout mice. Conclusion: NO-NIF prevents renal dysfunction associated with endothelial dysfunction independently of the blood glucose lowering, and it might be a potential drug for the prevention of DN. Disclosure of Interest: None declared. Few studies have assessed the real-life impact of secondary prevention drugs on all-cause mortality postmyocardial infarction (MI), especially in countries with low incidence of MI. The objective of this interim analysis after 3.5-year of follow-up was to assess the real-life all-cause mortality impact of drugs reimbursed for MI secondary prevention in France: acetylsalicylic acid (ASA), antiplatelet agents (APA), beta-blockers (ß-), angiotensin-converting enzyme inhibitors (ACEI), statins, and omega-3 supplementation (Om3) Patients (or Materials) and Methods: Cohort study of patients with recent (≤3 months) acute MI included by hospital and nonhospital cardiologists, with 6-year follow-up. Vital status was obtained from the National death registry, and failing that by patient/relatives/physicians investigation. Drug exposure was defined using both physician and patient reports at inclusion. Cox proportional hazards model was used to estimate for each drug, mortality hazard ratio (HR) of exposed versus nonexposed patients, adjusted for gender, age, cardiovascular risk factors, other MI prevention drugs, and propensity score to be exposed at inclusion. Results presented concern an interim analysis after 3.5 years of follow-up. 
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Results

Conclusion:
The 3.5-year interim all-cause real-life death reduction point estimates were close to those of large randomized controlled trials, except for ASA, for which almost all patients were exposed. The study's statistical power will be sufficient to confirm or not these trends at the final 6-year analysis. Disclosure of Interest: None declared. Effective flow through conduit arteries is important both for in situ organ perfusion and for tissue function after surgical and other procedures for revascularization. Membrane-bound, calcium-independent phospholipase A2 (iPLA2β ) has been implicated in G-protein coupled receptor-mediated vasoconstriction in experimental studies using Sbromoenolactone (S-BEL) as a probe. However, the role of iPLA2β is unclear with regard to the regulation of vascular tone in humans. S-BEL selectively inhibits iPLA2β . It also inhibits other serine hydrolases, including phosphatidate phosphohydrolase-1 (PAP-1). Patients (or Materials) and Methods: We studied human internal mammary (IMA) arteries obtained during coronary artery surgery and assessed iPLAβ in silico and responses in vitro to S-BEL, its enantiomer R-BEL, and propranolol of vessels preconstricted with phenylephrine (PE) to 80% of maximum response. All patients were undergoing surgery for treatment of ischemic heart disease and gave written informed consent to the study, which was approved by the local research ethics committee. Data are shown as means and standard errors. Data were compared by paired (Wilcoxon) or multi-way (Friedman) nonparametric tests. Introduction: Hypertension (HBP) is a disease with high morbidity and mortality worldwide and is a major etiological factor in heart and vascular diseases. An important regulatory mechanism of blood pressure (BP) is the renin angiotensin system (RAS). In fact, all the firstline drugs for the treatment of hypertension act on some component of the RAS. However, these treatments frequently lead to the development of changes in morphology and physiology characterized by vascular complications. It is therefore necessary to consider adjuvant therapies to improve the outcome of treatments and therefore in the quality of life of patients with HBP. A therapy that has been shown to improve the clinical condition of patients with HBP is hyperbaric oxygenation (HBO), in which the patient is subject to a pressure of 2 atmospheres absolute with an oxygen concentration of 100%. This therapy has been shown to improve vascular smooth muscle relaxation, although the mechanism of action has not yet been specified. The aim of this study is to examine the role of the RAS in the relaxation of vessels in hypertensive rats that is produced by HBO. Patients (or Materials) and Methods: Male Wistar rats were used (340 ± 20 g) at standard conditions (light/dark cycle, water and food ad libitum), and hypertension was induced by a previously described surgical method (PAGE). Stable hypertension was established at 7 days' postsurgery (for plethysmographic method). On the eighth day, HBO therapy began, and was carried out 5 days per week for 4 weeks. Rats were sacrificed at the end of treatment, obtaining thoracic and abdominal aorta. The endothelium was removed by a mechanical method, aortic rings were mounted, and concentration response curves were constructed according to increasing doses of ANG II for all groups with and without HBO. The results are analyzed with 2-way ANOVA and post hoc Von Ferroni. Results: Diastolic pressure was found to be 150 (10) mm Hg, consistent with the definition of hypertension. The angiotesin contractile response was lower in the groups of rats treated with HBO, compared with the 2 control groups (untreated and SHAM animals).
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Conclusion: HBO therapy reduced vascular reactivity in both segments of the hypertensive rat aorta. This suggests that HBO could possibly be used with hypertensive patients to reduce the use of drugs in therapy. Disclosure of Interest: None declared.
